https://www.selleckchem.com/pr....oducts/avitinib-ac00
ent surgery, RMB may provide additional risk stratification as these patients had lower rates of low-grade disease. To evaluate the utility of the Aorta-Lesion-Attenuation-Difference (ALAD) and Peak Early-phase Enhancement Ratio (PEER) on contrast-enhanced computed tomography (CT) to differentiate between the appearances of chromophobe renal cell carcinoma, clear cell renal cell carcinoma, and oncocytoma. ALAD and PEER values were retrospectively measured by a reviewer from 119 patients with surgically resected renal masses (chr